↓ Skip to main content

Dove Medical Press

Article Metrics

A review of the clinical efficacy and safety of MP-AzeFlu, a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate, in clinical studies conducted during different…

Overview of attention for article published in Journal of Asthma and Allergy, July 2016
Altmetric Badge

About this Attention Score

  • Among the highest-scoring outputs from this source (#41 of 105)
  • Above-average Attention Score compared to outputs of the same age (64th percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
4 tweeters

Citations

dimensions_citation
9 Dimensions

Readers on

mendeley
27 Mendeley
Title
A review of the clinical efficacy and safety of MP-AzeFlu, a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate, in clinical studies conducted during different allergy seasons in the US
Published in
Journal of Asthma and Allergy, July 2016
DOI 10.2147/jaa.s98172
Pubmed ID
Authors

Bruce Prenner

Abstract

A novel intranasal formulation of azelastine HCl (AZE, an antihistamine) and fluticasone propionate (FP, a corticosteroid) in a single spray (MP-AzeFlu [Dymista®]) was studied in four randomized, double-blind, placebo-controlled trials of patients with seasonal allergic rhinitis conducted in the US. Study sites were distributed so that all major US geographic regions and the prevalent pollens within these regions were represented. Spring and summer studies included patients aged 12 years and older with allergy to grass and tree pollens. Fall studies enrolled patients with allergy to weeds, in particular ragweed. In addition, a study was conducted during the winter months in patients with allergy to mountain cedar pollen in TX, USA. Regardless of allergy season or prevalent pollen, MP-AzeFlu improved nasal symptoms of allergic rhinitis (AR) to a significantly greater degree than AZE or FP, two treatments that currently are recommended as the first-line AR therapy. MP-AzeFlu improved all individual AR symptoms and was significantly better than FP and AZE for nasal congestion relief, which is generally accepted as the most bothersome symptom for AR patients. The onset of action was within 30 minutes. MP-AzeFlu also provided clinically important improvement in the overall Rhinoconjunctivitis Quality of Life Questionnaire score and significantly improved ocular symptoms of rhinitis compared to placebo. Favorable characteristics of the MP-AzeFlu formulation as well as superior clinical efficacy make it an ideal intranasal therapy for AR.

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 27 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 27 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 5 19%
Other 4 15%
Student > Doctoral Student 3 11%
Student > Bachelor 3 11%
Student > Postgraduate 3 11%
Other 4 15%
Unknown 5 19%
Readers by discipline Count As %
Medicine and Dentistry 9 33%
Pharmacology, Toxicology and Pharmaceutical Science 4 15%
Biochemistry, Genetics and Molecular Biology 3 11%
Nursing and Health Professions 2 7%
Immunology and Microbiology 1 4%
Other 1 4%
Unknown 7 26%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 July 2016.
All research outputs
#3,188,852
of 8,072,037 outputs
Outputs from Journal of Asthma and Allergy
#41
of 105 outputs
Outputs of similar age
#89,663
of 258,647 outputs
Outputs of similar age from Journal of Asthma and Allergy
#3
of 6 outputs
Altmetric has tracked 8,072,037 research outputs across all sources so far. This one has received more attention than most of these and is in the 60th percentile.
So far Altmetric has tracked 105 research outputs from this source. They receive a mean Attention Score of 4.3. This one has gotten more attention than average, scoring higher than 60% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 258,647 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 64% of its contemporaries.
We're also able to compare this research output to 6 others from the same source and published within six weeks on either side of this one. This one has scored higher than 3 of them.